Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis

Fig. 2

NRF2-regulated GPX4 was increased and associated with poor prognosis in AML. (a) The expression of GPX4 in MV4;11 cells transfected with LV-NC or LV-NRF2 was detected by western blotting. (b) The expression of GPX4 in MV4;11 cells transfected with shNC or shNRF2 was detected by western blotting. (c) The expression levels of NRF2(NFE2L2) (left panel) and GPX4 (middle panel) in HIs’ PBMCs and AML patients’ bone marrow mononuclear cells (BMMCs) were detected by qRT-PCR, and the GPX4 expression in AML cell lines (right panel) was detected by qRT-PCR. (d) Spearman correlation analysis of the NFE2L2 and GPX4 expression in AML patients’ BMMCs. (e) Overall survival analysis was performed on high-NFE2L2 or low-NFE2L2 and high-GPX4 or low-GPX4 expression groups in the AML patient cohorts in TCGA dataset, indicating the potential prognostic value of NRF2 and GPX4 expression in AML patients. (f) MV4;11 cells were treated with the indicated concentrations of ML385 for 24 h, and the expression of GPX4 was detected by western blotting. (g) MV4;11, Kasumi-1, and KG1α cells were administered with the indicated concentrations of ML385 for 24, 48, 72 h, and cell viability was detected by the CCK8 assay. Data are expressed as mean ± SD. n = 3 or more independent biological replicates, presented as individual points. P value < 0.05 was considered significant (a, c, two-tailed unpaired Student’s t test; b, f, one-way ANOVA with Dunnett’s post hoc test; e, log-rank test; g, one-way ANOVA with Bonferroni post hoc test).

Back to article page